Dishman Pharma Receives TGA Approval For API Production

Published: 17-Mar-2010

Dishman Pharmaceuticals and Chemicals, a manufacturer of active pharmaceutical ingredients (API), intermediates, quaternary compounds, and crown ethers, has said that its Bavla facilities are approved by Therapeutic Goods Administration (TGA), Department of Health and Ageing of government of Australia, for the production of all APIs, reported MyIris.

Dishman Pharma, through synthetic chemistry research, has developed manufacturing processes for various intermediates, APIs, quarternary ammonium compounds (QUATS) and specialty chemicals.

Dishman is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and manufacturing services. The products and services offered span customers’ needs from chemical development to commercial manufacture and supply of active pharmaceutical ingredients. Dishman has customer base in Europe, China and India

Recently, Dishman's Ahmedabad-based EOU facility had received the US FDA nod for API production.

The Dishman group consists of five different business units: Specialty Chemicals located in India, China; Carbogen Amics in Switzerland, UK, India; Contract Research and Manufacturing (CRAMS) in India, China; Vitamins & Chemicals in Netherlands, India; and Disinfectants in India, Australasia, Saudi Arabia.

No items to display

Tell your friend about this article